27712587|t|TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway
27712587|a|Tumor necrosis factor-α (TNF-α)-induced protein 8-like 2 (TNFAIP8L2, TIPE2) is involved in the invasion and metastasis of human tumors. However, the functional role of TIPE2 in prostate cancer remains unclear. In the present study, we explored the role of TIPE2 in prostate cancer and cancer progression including the molecular mechanism that drives TIPE2 -mediated oncogenesis. Our results showed that TIPE2 was lowly expressed in human prostate cancer tissues and cell lines. In addition, restored TIPE2 obviously inhibits proliferation in prostate cancer cells. TIPE2 overexpression also suppresses the epithelial-mesenchymal transition (EMT) process and migration / invasion in prostate cancer cells. Mechanistically, TIPE2 overexpression obviously inhibits the phosphorylation levels of phosphatidylinositol 3-kinase (PI3K) and Akt in prostate cancer cells. In conclusion, for the first time we demonstrated that TIPE2 overexpression may suppress proliferation, migration, and invasion in prostate cancer cells by inhibiting the PI3K/Akt signaling pathway. Therefore, TIPE2 might serve as a potential therapeutic target for human prostate cancer.
27712587	0	5	TIPE2	T103	UMLS:C2975187
27712587	6	20	Overexpression	T038	UMLS:C1514559
27712587	51	60	Migration	T038	UMLS:C1533574
27712587	66	74	Invasion	T033	UMLS:C1269955
27712587	78	93	Prostate Cancer	T038	UMLS:C0376358
27712587	94	99	Cells	T017	UMLS:C0334227
27712587	103	113	Inhibiting	T038	UMLS:C0021469
27712587	141	197	Tumor necrosis factor-α (TNF-α)-induced protein 8-like 2	T103	UMLS:C2975187
27712587	199	208	TNFAIP8L2	T103	UMLS:C2975187
27712587	210	215	TIPE2	T103	UMLS:C2975187
27712587	236	244	invasion	T033	UMLS:C1269955
27712587	249	259	metastasis	T038	UMLS:C0027627
27712587	263	268	human	T204	UMLS:C0086418
27712587	269	275	tumors	T038	UMLS:C0027651
27712587	309	314	TIPE2	T103	UMLS:C2975187
27712587	318	333	prostate cancer	T038	UMLS:C0376358
27712587	366	371	study	T062	UMLS:C2603343
27712587	397	402	TIPE2	T103	UMLS:C2975187
27712587	406	421	prostate cancer	T038	UMLS:C0376358
27712587	426	444	cancer progression	T038	UMLS:C1947901
27712587	459	478	molecular mechanism	T038	UMLS:C3537153
27712587	491	496	TIPE2	T103	UMLS:C2975187
27712587	507	518	oncogenesis	T038	UMLS:C0007621
27712587	524	531	results	T033	UMLS:C0456984
27712587	544	549	TIPE2	T103	UMLS:C2975187
27712587	560	569	expressed	T038	UMLS:C1171362
27712587	573	578	human	T204	UMLS:C0086418
27712587	579	594	prostate cancer	T038	UMLS:C0376358
27712587	595	602	tissues	T017	UMLS:C0040300
27712587	607	617	cell lines	T017	UMLS:C0085983
27712587	641	646	TIPE2	T103	UMLS:C2975187
27712587	657	665	inhibits	T038	UMLS:C0021469
27712587	683	698	prostate cancer	T038	UMLS:C0376358
27712587	699	704	cells	T017	UMLS:C0334227
27712587	706	711	TIPE2	T103	UMLS:C2975187
27712587	712	726	overexpression	T038	UMLS:C1514559
27712587	747	780	epithelial-mesenchymal transition	T038	UMLS:C1523298
27712587	782	785	EMT	T038	UMLS:C1523298
27712587	799	808	migration	T038	UMLS:C1533574
27712587	811	819	invasion	T033	UMLS:C1269955
27712587	823	838	prostate cancer	T038	UMLS:C0376358
27712587	839	844	cells	T017	UMLS:C0334227
27712587	863	868	TIPE2	T103	UMLS:C2975187
27712587	869	883	overexpression	T038	UMLS:C1514559
27712587	894	902	inhibits	T038	UMLS:C0021469
27712587	907	922	phosphorylation	T038	UMLS:C0031715
27712587	933	962	phosphatidylinositol 3-kinase	T103	UMLS:C2936824
27712587	964	968	PI3K	T103	UMLS:C2936824
27712587	974	977	Akt	T103	UMLS:C0164786
27712587	981	996	prostate cancer	T038	UMLS:C0376358
27712587	997	1002	cells	T017	UMLS:C0334227
27712587	1059	1064	TIPE2	T103	UMLS:C2975187
27712587	1065	1079	overexpression	T038	UMLS:C1514559
27712587	1108	1117	migration	T038	UMLS:C1533574
27712587	1123	1131	invasion	T033	UMLS:C1269955
27712587	1135	1150	prostate cancer	T038	UMLS:C0376358
27712587	1151	1156	cells	T017	UMLS:C0334227
27712587	1160	1170	inhibiting	T038	UMLS:C0021469
27712587	1214	1219	TIPE2	T103	UMLS:C2975187
27712587	1259	1265	target	T103	UMLS:C1513403
27712587	1270	1275	human	T204	UMLS:C0086418
27712587	1276	1291	prostate cancer	T038	UMLS:C0376358